Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies
Novartis $NVS has been noticeably absent from the center ring of PD-1/L1 research, quietly advancing its own checkpoint as an in-house asset to match up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
